mutant-selective pi3k-alpha h1047r inhibitor loxo-783
Generic: Mutant-selective PI3K-alpha H1047R Inhibitor LOXO-783
mutant-selective pi3k-alpha h1047r inhibitor loxo-783: 1 clinical trial tracked.
mutant-selective pi3k-alpha h1047r inhibitor loxo-783 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about mutant-selective pi3k-alpha h1047r inhibitor loxo-783, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trials (1)
A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation
Primary endpoint: Phase 1 a: To determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of LOXO-783: Number of patients with dose-limiting toxicities (DLTs)
Interventionalopen260 targetStarted 2022-05Completion 2026-1250 sites · Australia, Belgium, Canada, China…Eli Lilly and Company